OCT 23, 2017 5:10 AM PDT

Sex Chromosomes to Blame for Women's Risk of Autoimmune Diseases

WRITTEN BY: Kara Marker

Why are women more likely to have an autoimmune disease? It may literally be in their genes. A new study suggests that when a process to balance out genes from the “extra” X chromosome found in females goes awry, dysfunction in the immune system can lead to autoreactive diseases.

Researchers found that the protein YY1 brings Xist RNA back to the inactive X chromosome to maintain X chromosome inactivation in stimulated B cells. Activated, wild type B cells from female mice tightly localize Xist RNA at their inactive X chromosomes (left), whereas Xist RNA becomes dispersed throughout the entire nucleus when YY1 is deleted (right). Source: University of Pennsylvania

The genetic difference between males and females, as most people know, is that males have two different sex chromosomes (X, Y) and females have two of the same chromosome (X, X). However, females don’t need genes on both X chromosomes to be expressed, so a random process called X chromosome inactivation results in one X chromosome being invisible, often called a barr body. If the process is successful, no genes from the barr body are expressed. Now, researchers have reason to believe that some genes on the barr body, the “inactive X,” in immune cells are being expressed. And with extra immune genes being activated, autoimmune responses can develop.

From the University of Pennsylvania, scientists looked at the repercussions of an “extra dose” of “immunity-related gene expression” from the inactive X.

They build upon past findings that showed how the X chromosome inactivation process in female B and T cells often failed to reach completion. This was due to a long non-coding RNA (lncRNA) called Xist that failed to “initiate and maintain” the process. However, this failure was only before the immune cells were stimulated in response to an infection. The priming that takes place to prepare immune cells for the immune response, for whatever reason, caused Xist to (finally) show up in the right place.

“B cells are the ones making antibodies and autoantibodies, so they're really crucial in both protective immune responses and autoimmunity," described senior author Montserrat C. Anguera. "A big question that remains is, why are these immune cells priming for this chromosome to be regulated differently and also, if these processes go awry, how does that lead to autoimmunity and loss of self-tolerance?"

To answer these questions, the present study began to identify the factor that brings Xist RNA back during immune cell activation. Researchers actually tracked Xist during B cell development in female mice. At the beginning of development, the cells that come before full-fledged B cells - hematopoietic stem cells, common lymphoid precursors - at first seemed to show “clear patterns of Xist RNA on the inactive X chromosome.” But at some point Xist disappeared and reappeared, but when it came back, it was not in the place it needed to be to initiate X chromosome inactivation.

While tracking Xist, they also saw that an absence of heterochromatin modifications, “small-molecule tags” associated with gene repression during X chromosome inactivation.

Xist gathered in the inactive X during B cell activation, finally entering into a position capable of beginning X chromosome inactivation. Researchers pinned down the return of Xist to two different phases:

  1. Between four and 16 hours after B cell stimulation they saw “speckles” of Xist

  2. Between 16 and 30 hours after stimulation, they saw Xist “concentrated exclusively” at the inactive X

In addition, heterochromatin modifications increased and gathered in the second phase too.

During the study, researchers also realized how important it was for transcription factor YY1 to be involved. In mice B cells lacking YY1, researchers observed “greatly reduced levels of heterochromatin marks” and reduced “localization of Xist RNA to the inactive X.” This result signified to the researchers how the DNA binding activity of YY1 must be responsible for transporting Xist RNA back to the inactive X.

"It seems to be acting as a tether, bringing the Xist RNA together with the DNA of the inactive X chromosome," Anguera explained. "If you want to develop a therapy for autoimmune diseases, the idea is, how do we get Xist to the inactive X chromosome and keep it there so we maintain dosage compensation in these B cells. Certainly YY1 is looking like a really promising target."

The present study was published in the journal PLOS Genetics.

Learn more about the process of X chromosome inactivation:

Source: University of Pennsylvania

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
JUL 13, 2019
Cell & Molecular Biology
JUL 13, 2019
Learning More About the Causes of Endometriosis Pain
Endometriosis can be an extremely painful disorder that significantly impacts quality of life....
SEP 24, 2019
SEP 24, 2019
Flu Shot Less Effective Due to Overuse of Antibioitics
New research out of the Stanford University School of Medicine shows that the consequence of overuse of antibiotics lowers the effectiveness of the seasona...
OCT 12, 2019
OCT 12, 2019
Treating Alzheimer's? Target Microglia
The body’s own immune cells may be the common denominator in Alzheimer’s disease. In a new study of the relationship between microglia, tau pro...
OCT 31, 2019
OCT 31, 2019
Unpacking lactate's role in the Warburg effect
In a recent issue of Nature, the findings of one study made a particularly big splash: how and why cancer cells use energy differently than healthy cells. ...
NOV 26, 2019
NOV 26, 2019
The Immune System's Hand in Toxic Shock
While rare, toxic shock is a dangerous condition that acts fast and can be fatal. A new study identified a new target for treating toxic shock, a component...
NOV 28, 2019
Drug Discovery & Development
NOV 28, 2019
Immunotherapy Drug Shows Promise for Treating Advanced Prostate Cancer
By the end of the year, an estimated 175,000 men in the United States will have been diagnosed with prostate cancer. Now, researchers from the UK have foun...
Loading Comments...